Rhea N. Coler, Malcolm S. Duthie, Kimberly A. Hofmeyer, Jeffery Guderian et al.
Key antigens of Leishmania species identified in the context of host responses in Leishmania-exposed individuals from disease-endemic areas were prioritized for the development of a subunit vaccine against visceral leishmaniasis (VL), the most deadly form of leishmaniasis. Two Leishmania proteins-nu...
Malcolm S. Duthie, Lais Da Silva Pereira, Michelle A. Favila, Kimberly A. Hofmeyer et al.
Abstract Vaccine development for vector-borne pathogens may be accelerated through the use of relevant challenge models, as has been the case for malaria. Because of the demonstrated biological importance of vector-derived molecules in establishing natural infections, incorporating natural challenge...
Malcolm S. Duthie, Jeffery Guderian, Aarthy C. Vallur, Ajay Bhatia et al.
Until recently, chemotherapy for visceral leishmaniasis (VL; also known as kala-azar) was severely limited by factors such as high cost, route of administration, generation of side effects and potential for resistance. Although largely effective, chemotherapies have become available with the introdu...